# A Phase II Study Comparing Pegylated rhG-CSF（HHPG-19K） and rhG-CSF in Breast Cancer Patients Receiving Chemotherapy

> **NCT02119715** · PHASE2 · COMPLETED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 182 (actual)

## Conditions studied

- Breast Cancer
- Neutropenia
- Febrile Neutropenia

## Interventions

- **DRUG:** Pegylated rhG-CSF 100μg/kg
- **DRUG:** Pegylated rhG-CSF:150 μg/kg
- **DRUG:** rhG-CSF 5 μg/kg/day

## Key facts

- **NCT ID:** NCT02119715
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2012-08
- **Final completion:** 2012-12
- **Target enrollment:** 182 (ACTUAL)
- **Last updated:** 2014-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02119715

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02119715, "A Phase II Study Comparing Pegylated rhG-CSF（HHPG-19K） and rhG-CSF in Breast Cancer Patients Receiving Chemotherapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02119715. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*